AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.220
+0.090 (2.88%)
At close: Feb 19, 2026, 4:00 PM EST
3.222
+0.001 (0.05%)
After-hours: Feb 19, 2026, 7:56 PM EST
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $8.96M in the quarter ending September 30, 2025, with 37.62% growth. This brings the company's revenue in the last twelve months to $35.33M, up 7.17% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$35.33M
Revenue Growth
+7.17%
P/S Ratio
27.29
Revenue / Employee
$59,270
Employees
596
Market Cap
963.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.76B |
| Valneva SE | 211.09M |
| Phathom Pharmaceuticals | 147.19M |
| ARS Pharmaceuticals | 142.77M |
| CytomX Therapeutics | 113.63M |
| Theravance Biopharma | 80.33M |
| Evommune | 13.00M |
| Aktis Oncology | 5.56M |
ABCL News
- 8 days ago - AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Business Wire
- 4 weeks ago - AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 5 weeks ago - AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - Business Wire
- 2 months ago - AbCellera and Bruker Reach Global Settlement of Patent Litigation - Business Wire
- 2 months ago - AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha